Point72 Asset Management L.P. Has $4.60 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Point72 Asset Management L.P. trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 24.7% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 36,855 shares of the biotechnology company’s stock after selling 12,058 shares during the period. Point72 Asset Management L.P.’s holdings in Sarepta Therapeutics were worth $4,603,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in SRPT. Erste Asset Management GmbH acquired a new stake in shares of Sarepta Therapeutics during the 3rd quarter valued at about $79,425,000. Janus Henderson Group PLC raised its stake in shares of Sarepta Therapeutics by 14.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after acquiring an additional 543,143 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Sarepta Therapeutics by 693.7% in the 2nd quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock valued at $57,356,000 after acquiring an additional 317,277 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Sarepta Therapeutics by 146.3% in the 2nd quarter. Rhumbline Advisers now owns 270,941 shares of the biotechnology company’s stock valued at $42,809,000 after acquiring an additional 160,942 shares in the last quarter. Finally, Blair William & Co. IL raised its stake in shares of Sarepta Therapeutics by 303.7% in the 2nd quarter. Blair William & Co. IL now owns 174,282 shares of the biotechnology company’s stock valued at $27,537,000 after acquiring an additional 131,112 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now owns 5,880 shares in the company, valued at approximately $738,234. This represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 7.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Evercore ISI cut their price objective on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Needham & Company LLC lowered their price objective on Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating on the stock in a research report on Wednesday, November 27th. UBS Group boosted their price objective on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. HC Wainwright lowered their price objective on Sarepta Therapeutics from $80.00 to $75.00 and set a “sell” rating on the stock in a research report on Tuesday, December 3rd. Finally, StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average price target of $175.55.

Sarepta Therapeutics Trading Up 1.5 %

Shares of SRPT opened at $128.17 on Monday. The stock’s fifty day simple moving average is $122.71 and its 200-day simple moving average is $131.35. The firm has a market capitalization of $12.24 billion, a PE ratio of 102.54 and a beta of 0.77. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 12-month low of $85.61 and a 12-month high of $173.25.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.